Comment
. 2011 Feb 19;377(9766):635, author reply 636-7.
doi: 10.1016/S0140-6736(11)60223-7.
Paricalcitol for reduction of albuminuria in diabetes
- PMID: 21334524
- DOI: 10.1016/S0140-6736(11)60223-7
Item in Clipboard
Comment
Paricalcitol for reduction of albuminuria in diabetes
Lancet.
.
Free article
No abstract available
Comment on
-
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X. Lancet. 2010. PMID: 21055801 Clinical Trial.
Similar articles
-
Paricalcitol for reduction of albuminuria in diabetes.Lancet. 2011 Feb 19;377(9766):635, author reply 636-7. doi: 10.1016/S0140-6736(11)60222-5. Lancet. 2011. PMID: 21334526 No abstract available.
-
Paricalcitol for reduction of albuminuria in diabetes.Lancet. 2011 Feb 19;377(9766):635-6, author reply 636-7. doi: 10.1016/S0140-6736(11)60224-9. Lancet. 2011. PMID: 21334525 No abstract available.
-
Paricalcitol for reduction of albuminuria in diabetes.Lancet. 2011 Feb 19;377(9766):636, author reply 636-7. doi: 10.1016/S0140-6736(11)60225-0. Lancet. 2011. PMID: 21334527 No abstract available.
-
Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.Nat Clin Pract Nephrol. 2007 Apr;3(4):E2; discussion E3. doi: 10.1038/ncpneph0442. Nat Clin Pract Nephrol. 2007. PMID: 17389886 Review. No abstract available.
-
Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.Blood Purif. 2013;36(1):12-6. doi: 10.1159/000350579. Epub 2013 May 25. Blood Purif. 2013. PMID: 23736115 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
